1h Free Analyst Time
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018Speak directly to the analyst to clarify any post sales queries you may have.
Summary
According to the recently published report 'Integrin Alpha V - Pipeline Review, H2 2018'; Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) pipeline Target constitutes close to 31 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Integrin alpha-V is a protein encoded by the ITGAV gene. Alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits. The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin regulate angiogenesis and cancer progression.
The report 'Integrin Alpha V - Pipeline Review, H2 2018' outlays comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 6 and 18 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively.
Report covers products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Respiratory, Infectious Disease, Cardiovascular and Immunology which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Persistent Corneal Epithelial Defects, Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Liver Fibrosis, Metastatic Melanoma, Pancreatic Cancer, Wounds, Age Related Macular Degeneration, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Foot Ulcers, Diabetic Macular Edema, Genital Warts (Condylomata Acuminata), Malabsorption Syndrome, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Rheumatoid Arthritis, Sepsis and Venous Leg Ulcers (Crural Ulcer).
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)
- The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Overview
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Companies Involved in Therapeutics Development
Biogen Inc
BioMAS Ltd
BrightGene Bio-Medical Technology Co Ltd
Factor Therapeutics Ltd
MedImmune LLC
Merck & Co Inc
Merck KGaA
Morphic Therapeutic Inc
Pliant Therapeutics Inc
SciFluor Life Sciences LLC
Tasly Pharmaceutical Group Co Ltd
Vascular Pharmaceuticals Inc
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drug Profiles
264-RAD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abituzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Integrin Inhibit Alpha V and Beta 6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAT-2094 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BG-00011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGC-0222 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-16Y - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cilengitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CWHM-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize Integrin Alpha V Beta 3 and Integrin Alpha 5 Beta 1 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-0429 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSP-68 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOD-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OCU-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-74809 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proagio - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSF-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-0166 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ITGAV and ITGB1 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ITGAV and ITGB6 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha V for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetraiodothyroacetic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VF-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VF-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VF-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPI-2690B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Dormant Products
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Discontinued Products
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Product Development Milestones
Featured News & Press Releases
Oct 09, 2018: Merck KGaA to announce data of Abituzumab at ESMO 2018 Congress
Oct 04, 2018: Factor Therapeutics announce treatment completion marks milestone in Phase 2 clinical trial
Oct 02, 2018: Factor Therapeutics provides shareholder update Q3 2018
Sep 05, 2018: Factor Therapeutics announced phase 2 clinical trial for venous leg ulcers nears completion
Aug 06, 2018: Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis
Jul 19, 2018: Cassiopea announces top line positive proof of concept phase II results for CB-06-02 immune modulator in treating genital warts
Jul 16, 2018: Factor Therapeutics: Recruitment Completed in VF
Jun 26, 2018: VF00102 CLINICAL TRIAL UPDATE: Screening Closed to New Patients as Recruitment Nears Completion
Jun 14, 2018: Factor Therapeutics: VF001002 Clinical Trial Update
May 14, 2018: Factor Therapeutics announces its VF00102 Clinical Trial Recruitment Enters Final Phase
Apr 10, 2018: Factor Therapeutics Provides Update on VF00102 Clinical Trial
Dec 18, 2017: SciFluor announces positive top-line results of phase 1/2 study of SF0166 eye drops to treat wet age-related macular degeneration
Dec 12, 2017: SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts
Nov 29, 2017: Factor Therapeutics Announces 50% Recruitment Reached in VF00102 Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Biogen Inc, H2 2018
Pipeline by BioMAS Ltd, H2 2018
Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2018
Pipeline by Factor Therapeutics Ltd, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Merck KGaA, H2 2018
Pipeline by Morphic Therapeutic Inc, H2 2018
Pipeline by Pliant Therapeutics Inc, H2 2018
Pipeline by SciFluor Life Sciences LLC, H2 2018
Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2018
Pipeline by Vascular Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Dormant Products, H2 2018 (Contd..3), H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biogen Inc
- BioMAS Ltd
- BrightGene Bio-Medical Technology Co Ltd
- Factor Therapeutics Ltd
- MedImmune LLC
- Merck & Co Inc
- Merck KGaA
- Morphic Therapeutic Inc
- Pliant Therapeutics Inc
- SciFluor Life Sciences LLC
- Tasly Pharmaceutical Group Co Ltd
- Vascular Pharmaceuticals Inc
